Moleculin Announces Cardiac Safety Analysis Publication for Annamycin
Moleculin announced a peer-reviewed study showing no cardiotoxicity with Annamycin at cumulative doses exceeding traditional anthracycline limits, potentially validating its continued clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed